1. Home
  2. PLUG vs ZYME Comparison

PLUG vs ZYME Comparison

Compare PLUG & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plug Power Inc.

PLUG

Plug Power Inc.

N/A

Current Price

$1.04

Market Cap

1.9B

Sector

Energy

ML Signal

N/A

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

N/A

Current Price

$26.86

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLUG
ZYME
Founded
1997
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
1999
2022

Fundamental Metrics

Financial Performance
Metric
PLUG
ZYME
Price
$1.04
$26.86
Analyst Decision
Hold
Strong Buy
Analyst Count
19
14
Target Price
$3.12
★ $43.29
AVG Volume (30 Days)
★ 45.0M
1.0M
Earning Date
11-09-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 47.01
33.33
EPS
N/A
★ 1.08
Revenue
★ $709,919,000.00
$105,965,000.00
Revenue This Year
$15.76
$220.24
Revenue Next Year
$18.46
$6.44
P/E Ratio
★ N/A
$23.11
Revenue Growth
12.90
★ 38.87
52 Week Low
$1.00
$21.52
52 Week High
$4.33
$31.97

Technical Indicators

Market Signals
Indicator
PLUG
ZYME
Relative Strength Index (RSI) 27.51 46.04
Support Level N/A $22.28
Resistance Level $2.50 $27.40
Average True Range (ATR) 0.11 1.54
MACD -0.02 -0.45
Stochastic Oscillator 5.10 28.27

Price Performance

Historical Comparison
PLUG
ZYME

About PLUG Plug Power Inc.

Plug Power Inc is building an end-to-end green hydrogen ecosystem, from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: